Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) saw unusually-high trading volume on Monday. 3,864 shares changed hands during trading, an increase of 493% from the average daily volume of 652 shares. The stock last traded at $313.8125 and had previously closed at $317.34.
Analyst Ratings Changes
Several equities analysts have issued reports on the stock. Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Jefferies Financial Group upgraded UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Stephens reiterated an “overweight” rating on shares of UCB in a report on Wednesday, October 21st. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, UCB has an average rating of “Moderate Buy”.
View Our Latest Analysis on UCBJF
UCB Stock Down 1.1%
The company’s 50-day moving average price is $254.23 and its two-hundred day moving average price is $285.79. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.
About UCB
UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.
The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).
Featured Articles
- Five stocks we like better than UCB
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
